OUR SOLUTION
25 percent of lung cancer patients are candidates for surgery. AcuityBio’s drug-eluting polymer implant, ABC103, would be administered during initial tumor removal surgery and prevent recurrence.
Overview
ABC103: Demonstrated Efficacy Combines Approved Products
-
Safety and Efficacy in preclinical models
-
Excellent long-term (>60day) safety in rodent and large animal resection models (rabbit and pig)
-
-
Long-term targeted delivery of therapeutic levels of paclitaxel to areas at highest risk for harboring residual cancer cells
-
Compatibility with existing standard of care procedures approved devices using approved and efficacious drug preventing recurrence
Paclitaxel
-
Approved for use to treat many cancers including lung cancer
Biodegradable Polymers for Coating
-
Used in multiple FDA approved products
Staple line buttress
-
510K cleared
Platform Technology
ABC Technology can be used to deliver many compounds.
Our product candidate is based on technology developed and patented by AcuityBio; which can deliver many drugs and be applied to additional indications besides lung cancer.
Our technology can be applied to many delivery challenges please inquire about co-development opportunities